T1	p 66 97	adults with autistic disorder .
T2	p 109 126	Autistic disorder
T3	p 379 400	persons with autism .
T4	p 491 499	autism .
T5	p 508 556	Thirty adults with autistic disorder completed a
T6	p 799 813	15 patients in
T7	p 1251 1259	level of
T8	p 1283 1298	full-scale IQ .
T9	p 1559 1591	of autistic disorder in adults .
T10	p 1703 1741	children and adolescents with autism .
T11	i 23 41	placebo-controlled
T12	i 51 62	fluvoxamine
T13	i 580 598	placebo-controlled
T14	i 633 642	serotonin
T15	i 650 681	inhibitor fluvoxamine maleate .
T16	i 907 914	placebo
T17	i 936 947	Fluvoxamine
T18	i 964 971	placebo
T19	i 1032 1043	maladaptive
T20	i 1130 1136	social
T21	i 1355 1366	fluvoxamine
T22	i 1472 1483	Fluvoxamine
T23	i 1507 1514	placebo
T24	i 1614 1625	fluvoxamine
T25	i 1657 1666	serotonin
T26	o 176 194	social interaction
T27	o 268 292	activities and interests
T28	o 682 700	Behavioral ratings
T29	o 984 1016	repetitive thoughts and behavior
T30	o 1032 1052	maladaptive behavior
T31	o 1068 1082	and aggression
T32	o 1130 1148	social relatedness
T33	o 1163 1188	especially language usage
T34	o 1204 1222	Treatment response
T35	o 1260 1277	autistic behavior
T36	o 1280 1282	or
T37	o 1315 1334	sedation and nausea
T38	o 1376 1448	tolerated . No dyskinesias , adverse cardiovascular events , or seizures
T39	o 1550 1558	symptoms